Rudd E, Bryceson Y T, Zheng C, Edner J, Wood S M, Ramme K, Gavhed S, Gürgey A, Hellebostad M, Bechensteen A G, Ljunggren H-G, Fadeel B, Nordenskjöld M, Henter J-I
Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
J Med Genet. 2008 Mar;45(3):134-41. doi: 10.1136/jmg.2007.054288. Epub 2007 Nov 9.
Familial haemophagocytic lymphohistiocytosis (FHL) is a fatal disorder of immune dysregulation with defective cytotoxic lymphocyte function. Disease-causing mutations have been identified in the genes encoding perforin (PRF1), syntaxin-11 (STX11), and Munc13-4 (UNC13D). We screened for UNC13D mutations and studied clinical and functional implications of such mutations in a well defined patient cohort.
Sequencing of UNC13D was performed in 38 FHL patients from 34 FHL families in which PRF1 and STX11 mutations had been excluded.
We identified six different mutations affecting altogether 9/38 individuals (24%) in 6/34 (18%) unrelated PRF1/STX11-negative families. Four novel mutations were revealed; two homozygous nonsense mutations (R83X and W382X), one splice mutation (exon 28), and one missense mutation (R928P). In addition, two known mutations were identified (R214X and a deletion resulting in a frame-shift starting at codon 782). There was considerable variation in the age at diagnosis, ranging from time of birth to 14 years (median 69 days). Three of nine patients (33%) developed central nervous system (CNS) symptoms. Natural killer (NK) cell activity was impaired in all four patients studied. Defective cytotoxic lymphocyte degranulation was evident in the two patients investigated, more pronounced in the patient with onset during infancy than in the patient with adolescent onset.
Biallelic UNC13D mutations were found in 18% of the PRF1/STX11-negative FHL families. Impairment of NK cell degranulation was less pronounced in a patient with adolescent onset. FHL should be considered not only in infants but also in adolescents, and possibly young adults, presenting with fever, splenomegaly, cytopenia, hyperferritinaemia, and/or CNS symptoms.
家族性噬血细胞性淋巴组织细胞增生症(FHL)是一种因细胞毒性淋巴细胞功能缺陷导致的免疫调节异常的致命性疾病。已在编码穿孔素(PRF1)、 syntaxin-11(STX11)和Munc13-4(UNC13D)的基因中鉴定出致病突变。我们在一个明确的患者队列中筛查UNC13D突变,并研究此类突变的临床和功能意义。
对来自34个FHL家族的38例FHL患者进行UNC13D测序,这些家族已排除PRF1和STX11突变。
我们在6/34(18%)个不相关的PRF1/STX11阴性家族中鉴定出6种不同的突变,共影响9/38例个体(24%)。发现了4种新突变;2种纯合无义突变(R83X和W382X)、1种剪接突变(外显子28)和1种错义突变(R928P)。此外,还鉴定出2种已知突变(R214X和一个导致从密码子782开始移码的缺失)。诊断年龄差异很大,从出生时到14岁(中位数69天)。9例患者中有3例(33%)出现中枢神经系统(CNS)症状。所研究的4例患者的自然杀伤(NK)细胞活性均受损。在2例受调查患者中,细胞毒性淋巴细胞脱颗粒存在缺陷,在婴儿期发病的患者中比青少年期发病的患者更明显。
在18%的PRF1/STX11阴性FHL家族中发现了双等位基因UNC13D突变。青少年期发病患者的NK细胞脱颗粒受损不太明显。对于出现发热、脾肿大、血细胞减少、高铁蛋白血症和/或CNS症状的患者,不仅应考虑婴儿,还应考虑青少年,甚至可能是年轻成人。